Modification of Acute Experimental Autoimmune Encephalomyelitis in the Lewis Rat by Oral Administration of Type 1 Interferons

Journal of Interferon and Cytokine Research

Volumn 15, Issue 2, 1995, Pages 115-122

  Brod, Staley A ^a   Scott, Margaret ^b   Phillips, J T ^b   Burns, Dennis K ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTIMMUNE; GAMMA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMAL; CELLS, CULTURED; COMPARATIVE STUDY; CONCANAVALIN A; ENCEPHALOMYELITIS, EXPERIMENTAL AUTOIMMUNE; FEMALE; FREUND'S ADJUVANT; GUINEA PIGS; INTERFERON TYPE I; INTERFERON TYPE I, RECOMBINANT; INTERFERON TYPE II; INTERFERON-ALPHA; INTERFERON-BETA; LYMPH NODES; LYMPHOCYTE ACTIVATION; MYELIN BASIC PROTEINS; RATS; RATS, INBRED LEW; SPLEEN; SUPPORT, NON-U.S. GOV'T;

EID: 0028964995     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.1995.15.115     Document Type: Article

References (35)

1. ALVORD, E.C., SHAW, C.M., HUBY, S., and KIES M.W. (1965). Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression and therapy. Ann N.Y. Acad. Sci. 122, 333-345.
2. ABREU, S.L. (1982). Suppression of experimental allergic encephalomyelitis by interferon. Immunol. Commun. 11, 1-7.
3. ABREU, S.L., TONDREAU, J., LEVINE, S., and SOWINSKI, R. (1983). Inhibition of passive localized experimental allergic, encephalomyelitis by interferon. Int. Arch. Allergy Appl. Immunol. 72, 30-33.
4. JOHNS, L.D., FLANDERS, K.C., RANGES, G.E., and SR-IRAM, S. (1991). Successful therapy of experimental allergic encephalomyelitis with transforming growth factor-p,. J. Immunol. 147, 1792-1796.
5. CUMMINS, J.M., TOMPKINS, M.B., OLSEN, R.G., TOMPKINS, W.A., and LEWIS, M.G. (1988). Oral use of human alpha interferon in cats. J. Biol. Response Modifiers 7, 513-523.
6. YOUNG, A.S., and CUMMINS, J.M. (1990). The history of interferon and its use in animal therapy. East Afr. Med. J. 67(Suppl.2), S531-S563.
7. BROD, S. A., and BURNS, D.H. (1994). Suppression of relapsing experimental allergic encephalomyelitis in SJL/L mouse by oral administration of type 1 interferons. Neurology 44,1144-1148.
8. HIGGINS, P., and WEINER, H.L. (1988). Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 140, 440-445.
9. BROD, S.A., AL-SABBAGH, A., SOBEL, R.A., and WEINER, H.L. (1991). Suppression of relapsing experimental allergic encephalomyelitis in Lewis rats and strain 13 guinea pigs by oral administration of myelin antigens. Ann. Neurol. 29, 615-622.
10. DURELLI, L., BONGIOANNI, M.R., CAVALLO, R., FERRARO, B., FERRI, R., FERRIO, M.F., BRADAC, A. RIVA, G.B., VAI, S., GEUNA, M., BERGNAMI, L., and BERGAMASCO, B. (1994). Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relaps-ing-remitting multiple sclerosis. Neurology 44,406-413.
11. TABATA, Y., UNO, K., YAMAOKA, T., IKADA, Y., and MURAMATSU, S. (1991). Effects of recombinant alpha inter- feron gelatin conjugate on in vivo murine tumor cell growth. Cancer Res 51,5532-5538.
12. SHIBATA, M., and BLATTEIS, C.M. (1991). Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum lamina terminal!s. Brain Res. 562, 323-326.
13. DENNIS, M.J., THOMAS, L.H., and STOTT, E.J. (1991). Effects of recombinant human alpha A interferon in gnotobiotic calves challenged with respiratory syncyntial virus. Res. Vet. Sci. 50, 222-228.
14. HORISBERGER, M.A., and GUNST, M.C. (1991). Interferon induced proteins: identification of Mx proteins in various mammalian species. Virology 180, 185-190.
15. WEISS, R.C., and OOSTROM-RAM, T. (1990). Effects of recombinant human interferon alpha in vitro and in vivo on mitogen induced by lymphocyte blastogenesis in cats. Vet. Immunol. Im-munopathol. 24, 147-157.
16. MCDONALD, A.H., and SWANBORG, R.H. (1988). Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J. Immunol. 140, 1132-1138.
17. DIEZ, R.A., PERDEREAU, B., and FALCOFF, E. (1987). From old results to new perspectives: a look at interferons fate in the body. J. Interferon Res. 7, 553-557.
18. KADISH, A.S., TANSEY, F.A., YU, G.S.M., DOYLE, A.T., and BLOOM, B.R. (1980). Interteron as a mediator of human lymphocyte suppression. J. Exp. Med. 151, 637-650.
19. AUNE, T.M., and PIERCE, C.W. (1982). Activation of a suppressor T cell pathway by interferon. Proc. Natl. Acad. Sci. USA 79, 3808-3812.
20. STOBO, J., GREEN, I., JACKSON, L., and BARON, S. (1974). Identification of a subpopulation of mouse lymphoid cells required for interferon production after stimulation with mitogens. J. Immunol. 112,1589-1593.
21. GIBSON, D.M., COTLER, S., SPIEGEL, H.E., and COLBURN, W.A. (1985). Pharmacokinetics of recombinant leucocyte A interferon following various routes and modes of administration to the dog. J. Interferon Res. 5,403-408.
22. WILLS, R.J., SPIEGEL, H.E., SOIKE, K.F. (1984). Pharmacokinetics of recombinant leucocyte A interferon following IV infusion and bolus, IM, and PO administration to African green monkeys. J. Interferon Res. 4, 399-409.
23. WITT, P.J., GOLDSTEIN, D., STORER, B.E., GROSSBERG, S.E., FLASHNER, M., COLBY, C.B., and BORDEN, E.C. (1992). Absence of biological effects of orally administered inter-feron-βset* J. Int. Res. 12, 411-413.
24. FLEISCHMANN, W.R., KOREN, S., and FLEISCHMANN, C.M. (1992). Oral administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 199-207.
25. SEITZ, M., NAPIERSKI, I., AUGUSTIN, R., HUNSTEIN, W., and KIRCHNER, H. (1987). Reduced production of interferon alpha and interferon gamma in leukocyte cultures from patients with active rheumatoid arthritis. Scand. J. Rheumatol. 16, 257-262.
26. KAPP, A., GILLITZER, R., KIRCHNER, H., and SCHOPF, E. (1988). Decreased production of interferon in whole blood cultures derived from patients with psoriases. J. Invest. Dermatol. 90, 511-514.
27. KAPP, A., GILLITZER, R., KIRCHNER, H., and SCHOPF, E. (1987). Production of interferon and lymphoproiiferative response in whole blood cultures derived from patients with atopic dermatitis. Arch. Dermatol. Res. 279(Suppl. S), 55-58.
28. HERTZOG, P.J., WRIGHT, A., HARRIS, G., LINNANE, A.W., and MACKAY, I.R. (1988). Intermittent interferonemia and interferon responses in multiple sclerosis. Clin. Immunol. Immunopathol 58, 18-32.
29. MARUO, Y. (1988). Interferon production and natural killer activity of peripheral blood lymphocytes obtained from patients with multiple sclerosis. Hokkaido J. Med. Sci. 63, 521-533.
30. VRANES, Z., POUAKOVIC, Z., and MARUCIC, M. (1989). Natural killer cell number and activity in multiple sclerosis. J. Neurol. Sci. 94, 115-123.
31. KASTRULOFF, L.F., MORGAN, N.G., AZIZ, T.M., ZECCHINI, D., BERKOWITZ, J., and PATY, D.W. (1988). Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. J. Neuroimmunol. 20, 15-23.
32. PANITCH, H.S. (1987). Systemic alpha-interferon in multiple sclerosis: long term patient follow-up. Arch. Neurol. 44, 61-63.
33. KNOBLER, R.L. (1988). Systemic interferon therapy of multiple sclerosis: the pros. Neurology 38, 58-61.
34. KASTRULOFF, L.F., OGER, J.J., HASHIMOTO, S.A., SACKS, S.L., LI, D.K., PALMER, M.R., KOOPMANS, R.A., PETKAU, A.J., BERKOWITZ, J., and PATY, D.W. (1990). Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. 1. Clinical and MRI evaluation. Neurology 40, 479-486.
35. IFNB MS Study Group. (1993). Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 43, 655-660.